Biomedtracker and Datamonitor Healthcare present a post-summit dispatch for the 23rd Bio Asia International Summit, Asia's premier life sciences and health-tech forum, held in Hyderabad, India, from February 16-18, 2026. Key highlights include:

·       TechBio is redefining drug discovery: The convergence of AI, automation, and large-scale biological data is shifting the industry from traditional experimentation to predictive, design-driven therapeutic development.

·       Advanced modalities are driving future growth: Gene therapies, cell therapies, mRNA platforms, and precision oncology are moving from experimental innovation to clinically validated treatment approaches.

·       Scaling innovation requires integrated ecosystems: To deliver these therapies globally, companies must align discovery, regulatory strategy, and manufacturing while addressing affordability, access, and infrastructure challenges.

This post-meeting report features commentary from our analysts on specific plenary presentations and panel discussions.